<DOC>
	<DOCNO>NCT01321827</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety itraconazole monotherapy patient ABPA .</brief_summary>
	<brief_title>Monotherapy Itraconazole Versus Prednisolone Allergic Bronchopulmonary Aspergillosis</brief_title>
	<detailed_description>Allergic bronchopulmonary aspergillosis ( ABPA ) pulmonary disorder cause complex hypersensitivity response antigen release fungus Aspergillus fumigatus . The clinical entity first describe Hinson et al 1952 , clinical immunologic significance Aspergillus fumigatus sputum report Pepys coworkers 1959 . The prevalence ABPA bronchial asthma fairly high recent meta-analysis suggest prevalence ABPA asthma clinic high 13 percent . Diagnostic criterion ABPA lay generally include follow eight major criterion : ( ) history asthma ; ( b ) transient fix pulmonary infiltrates ; ( c ) immediate cutaneous hyperreactivity A fumigatus antigen ; ( ) absolute eosinophil count &gt; 1000/µL ; ( e ) serum precipitins A fumigatus ; ( f ) total IgE level &gt; 1000 IU/mL ; ( g ) central bronchiectasis high-resolution compute tomography ( HRCT ) ; , ( h ) raise A fumigatus specific IgE IgG level . However , none specific ABPA , still consensus number criterion need diagnosis , patient different stage ABPA may fulfill criterion . Also , establish definition remission ABPA . The widely follow criterion clinical radiological improvement least 35 percent decline total serum IgE level . However , recent study investigator demonstrate 35 % decline serum IgE level six week see patient ABPA , decline slow patient baseline IgE level &lt; 2500 IU/mL . Moreover , quantum decline serum IgE level predict clinical outcome . The disorder highly prevalent India . The investigator previously report experience screen stable outpatient bronchial asthma acute severe asthma ABPA . The investigator also recently report prognostic factor associate clinical outcome patient ABPA . Oral corticosteroid currently treatment choice ABPA associate bronchial asthma . They suppress immune hyperfunction also anti-inflammatory . However , data guide dose duration glucocorticoid different regimen glucocorticoid use literature . Itraconazole , oral triazole relatively low toxicity , active Aspergillus spp . vitro vivo . The activity itraconazole Aspergillus spp . ketoconazole . The administration itraconazole eliminate Aspergillus airway theoretically reduce allergic response ABPA . The aim prospective randomize control trial ( RCT ) evaluate efficacy safety itraconazole monotherapy patient ABPA .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Aspergillosis , Allergic Bronchopulmonary</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Patients include study meet criterion ABPA define Presence follow three criterion : immediate cutaneous hyperreactivity aspergillus skin test elevate total IgE level &gt; 1000 IU/mL A fumigatus specific IgE level &gt; 0.35 kU/L Two follow criterion : presence serum precipitate antibody A fumigatus fix transient radiographic pulmonary opacity absolute eosinophil count &gt; 1000/µL central bronchiectasis HRCT . take glucocorticoid three week precede six month failure give informed consent enrollment another trial ABPA</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ABPA</keyword>
</DOC>